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Abstract
Background: Information on acute kidney injury (AKI) in elderly hospitalized patients is limited. This study aims to
assess the incidence, risk factors and outcomes of AKI in elderly Chinese patients.
Method: The Epidemiology of AKI in Chinese Hospitalized adults (EACH) study is a multicenter, retrospective cohort
study conducted in nine regional central hospitals across China. Patients aged more than 65 years were selected
from the EACH study for this analysis. A novel approach with adjustment for frequency of serum creatinine was
used to estimate the incidence of AKI in elderly patients. In-hospital outcomes, including mortality, renal recovery,
length of stay and daily cost of elderly patients, were analyzed and compared with outcomes in younger patients.
Results: Of 144,232 adult patients in the EACH study, 42,737 (29.63 %) patients were 65 years or older, including 9773
very elderly patients (≥80 years old). The incidence of AKI was 15.44 % in patients 65–79 years old (community-acquired
(CA) AKI of 3.89 % and hospital-acquired (HA) AKI of 11.55 %) and 22.22 % in the very elderly group (CA-AKI of 6.58 %
and HA-AKI of 15.64 %). The mortality rate of AKI was 10.3 % in patients aged from 65 to 80 and 19.6 % in patients older
than 80 years. AKI incidence, in-hospital mortality, percentage of patients requiring dialysis and percentage without renal
recovery were higher in elderly patients than in younger patients.
Conclusion: The incidence of AKI in elderly Chinese hospitalized patients is high, which becomes a substantial
burden on medical care in China.
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Background
Acute kidney injury (AKI) is a common disorder, charac-
terized by an abrupt or rapid decline in renal filtration
function. The incidence of dialysis-dependent AKI in-
creased by 10 % every year in the past decade [1]. How-
ever, the incidence of AKI in hospitalized patients varied
in different studies, depending on the definition of AKI,
frequency of serum creatinine (SCr) tests, clinical setting
of study population, and economical level of countries
[2–4]. In the Epidemiology of AKI in Chinese Hospital-
ized adults (EACH) study, by using a novel approach
with adjustment for the frequency of SCr tests and
other potential confounders, we have demonstrated
that the incidence of AKI is 11.6 % in China, the largest
developing country with 20 % of the world’s population
[5]. Of note, the detection rate of AKI was only 0.99 %
by KDIGO criteria without adjustment for the fre-
quency of SCr tests in another cross-section study and
under-diagnosis and under-treatment rates of AKI in
China are extremely high [6], which may lead to poor
outcomes for patients.
Elderly people have aging kidneys undergoing struc-
tural and functional changes that decrease auto regula-
tory capacity and increase susceptibility to damage [7].
The incidence rate of AKI is higher in the elderly popu-
lation than in younger populations, and age is a major
predictive factor of mortality in patients with AKI [8]. In
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addition to age-related changes in the kidney, mul-
tiple chronic comorbidities (chronic kidney disease,
cardiovascular disease, diabetes and sepsis), exposure
to nephrotoxic medications, oxidative stress, hypovol-
emia and surgery may account for the increased risk
of developing AKI in elderly hospitalized patients [9].
It has been demonstrated that there is a significantly
lower recovery rate of kidney function in elderly pa-
tients than in younger patients [10].
With the development of society and economy, life ex-
pectancy in China has increased to 73.5 years for males
and 79.9 years for females according to WHO data pub-
lished in 2013 [11]. Currently, nearly one in ten Chinese
is aged over 65, and this number will increase to one in
four by 2050, which will be a heavy burden on society.
However, there are few studies about AKI in the elderly
Chinese population [12–15]. In addition, several single-
center studies did not adjust the frequency of SCr tests,
which may have led to underestimation of the incidence
of AKI in hospitalized elderly Chinese patients [14, 15].
In this large retrospective cohort study of hospitalized
adults in China, we aimed to demonstrate the incidence
rate, risk factors and in-hospital outcomes of AKI in
elderly patients by using a novel analytical method to
minimize the impact of frequency of SCr tests.
Methods
Study design, setting and participants
A multicenter, retrospective cohort study (the EACH
study) was previously conducted [5]. Patients admitted
between January 1 and December 31, 2013 from nine re-
gional central hospitals across Northern, Central, and
Southern China were enrolled in the EACH study.
Patients with a history of stages 4–5 chronic kidney
disease (CKD), maintenance dialysis or renal trans-
plantation were excluded. Patients with less than two
SCr tests in a 7-day window during their first 30 days
of hospitalization were also excluded. Elderly patients
(aged more than 65 years) were selected from the cohort
for current analysis. The study protocol was approved by
the Medical Ethics Committee of Nanfang Hospital (No.
NFEC-2014-098). This study has adhered to the STROBE
guidelines on reporting of cross-sectional data.
Data sources
Clinical data including patient age, gender, admission
and discharge data, SCr values and test frequency, medi-
cation, surgical procedures and dates, in-hospital death,
and total cost were collected from electronic hospital
and laboratory databases. Nephrotoxic drug exposure
and other risk factors were assessed by trained nephrolo-
gists. The study protocol was approved by the medical
ethics committee of Nanfang Hospital.
Identification and classification of AKI
AKI was defined as an increase in SCr by 0.3 mg/dl within
48 h or a 50 % increase in SCr from the baseline within
7 days according to the KDIGO criteria [16]. Patients were
classified according to the KDIGO criteria as specified by
stage 1, stage 2 and stage 3. The date of AKI onset was de-
fined as the earliest day that the SCr change met the
KDIGO criteria. The stage of AKI was determined using
the peak SCr level after the date of AKI onset.
Community-acquired (CA) AKI was defined in the
clinical setting as meeting at least one of the following
criteria: (1) Patients were diagnosed with AKI on admis-
sion according to diagnosis code; (2) SCr change during
the first day of admission met the KDIGO definition; (3)
SCr on admission was ≥1.4 mg/dl in men or ≥1.1 mg/dl
in women and ≥1.5-fold of the baseline SCr level. The
baseline SCr was defined as the lowest SCr during
hospitalization for CA-AKI.
Hospital-acquired (HA) AKI was defined as AKI pa-
tients who did not meet the CA-AKI criteria. The base-
line SCr was defined as the mean of SCr levels within
the 7 days before AKI onset for HA-AKI.
Definition of outcomes
Patient outcomes included in-hospital death, renal re-
covery, requirement for RRT, length of stay (LOS) in
hospital and daily cost of hospitalization. Renal recovery
of AKI was defined as a decreasing SCr to within the
non-AKI range and at least 0.3 mg/dl below the peak
level without RRT.
Determination of comorbidity
The presence of comorbidities was identified by diagno-
sis codes at admission or past history in medical record.
The Charlson comorbidity score was used to assess the
burden of comorbidity.
Statistical analysis
Statistical analyses were performed using R software,
version 3.1.1, and the survival package, version 2.37, with
statistical significance set at P < 0.05. Categorical vari-
ables were summarized as number and percentage, and
continuous variables were expressed as the mean ±
standard deviation and median with interquartile range
(skewed distribution). One-way ANOVA was used for
continuous variables, and a X2 test was used for categor-
ical variables. Incidence of AKI was calculated by a novel
approach with adjustment for the frequency of SCr tests
[5]. Risk factors were determined by Cox proportional
hazard model. Population attributable fractions (PAF)
were used to assess the contribution of different risk fac-
tors to AKI. Cumulative rates of in-hospital death in the
subgroups were determined using the Kaplan–Meier
method by AKI status, and corresponding HRs were
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calculated using the Cox proportional hazard model
with adjustment for age, sex, comorbidities, and clin-
ical procedures.
Results
Of 144,232 patients aged over 18 years included in the
EACH cohort study, 42,737 (29.63 %) patients were
65 years or older, including 9773 (6.8 %) very elderly pa-
tients (≥80 years old). Characteristics of patients by age
category are provided in Table 1. Compared with the
younger group, elderly patients were more often male
and had a higher prevalence of CKD, especially in pa-
tients older than 80 years. In addition, the Charlson co-
morbidity index scores in the elderly group were higher
than in the younger group. The elderly group had a
much higher number and frequency of SCr tests, which
may lead to more frequent detection of AKI (Table 1).
Incidence of AKI
The incidence of AKI adjusted for the frequency of SCr
tests was 15.44 % in patients 65–80 years old (CA-AKI
of 3.89 % and HA-AKI of 11.55 %) and 22.22 % in the
very elderly group (CA-AKI of 6.58 % and HA-AKI of
15.64 %), whereas in the younger group, the incidence of
AKI was much lower (CA-AKI of 2.76 % and HA-AKI
of 8.78 %) (Table 1). In addition, there is a significant
correlation between AKI stage and the age of patients.
We identified a higher rate of AKI stage 1 and a lower
rate of AKI stage 3 in patients 65–80 year old (Table 1).
Risk factors for AKI
In patients older than 65 years, a significant association
between AKI incidence and age was observed in CA-
AKI groups (Table 2). Male patients were at increased
risk for AKI compared to female patients, especially for
HA-AKI. The PAF of the risk factors was used to assess
their contribution to AKI in elderly patients. The top
three risk factors for HA-AKI, ranked in order of de-
creasing PAF, were CKD, intensive care and heart failure.
CKD, pneumonia and shock were the top three risk fac-
tors for CA-AKI. Of note, CKD was a major contributor
to both HA-AKI (mean PAF of 24.8) and CA-AKI (mean
PAF of 26.5) (Table 2). The PAF of CKD in patients
older than 80 years is 30.7, which is much higher than
the PAF of 10.4 in younger groups, suggesting CKD is
an essential risk factor for elderly patients (Table 3).















Age (yr) 46.55 ± 12.43 71.33 ± 4.32 84.14 ± 3.64 <0.001 47.41 ± 12.34 71.76 ± 4.39 84.54 ± 3.71 <0.001
Male (%) 52.7 59.1 61.9 <0.001 59.5 60.7 61.1 0.25
Geographic location (%) <0.001 <0.001
Northern 26.1 27.9 25.1 28 28.2 25.3
Central 34 29.7 32.8 28.8 28.9 34.6
Southern 39.9 42.3 42.1 43.2 42.9 40.1
CKD (%) 3.2 12.5 26.1 <0.001 17.4 31.7 42.5 <0.001
Charlson comorbidity index 1.17 ± 1.32 1.56 ± 1.46 1.87 ± 1.65 <0.001 1.35 ± 1.44 1.92 ± 1.65 2.28 ± 1.8 <0.001
BaselineSCr (umol/L) 66.16 ± 23.49 76.82 ± 27.19 84.91 ± 29.44 <0.001 77.33 ± 41.48 84.26 ± 40.52 87.26 ± 36.18 <0.001
Peak SCr (umol/L) — — — — 180.1 ± 177.35 190.29 ± 170.84 198.31 ± 167.49 <0.001
No. of SCr tests 3.43 ± 2.48 3.4 ± 2.43 3.62 ± 2.96 <0.001 7.81 ± 8.11 7.65 ± 7.52 9.14 ± 13.44 <0.001
Frequency of SCr testa 0.39 ± 0.23 0.43 ± 0.26 0.43 ± 0.26 <0.001 0.49 ± 0.26 0.5 ± 0.27 0.53 ± 0.27 <0.001
AKI Subtypes (%)b — <0.001
CA-AKI — — — 2.76 3.89 6.58
HA-AKI — — — 8.78 11.55 15.64
AKI stage (%) — <0.001
1 — — — 56.6 60.7 59.4
2 — — — 20.1 20.4 21.2
3 — — — 23.3 18.9 19.4
ICU (%) 8.1 8.8 9.2 <0.001 31.3 31.7 29.2 0.19
Length of stay and daily cost are presented in median (25th, 75th percentile). Values expressed with a ± sign are presented as the mean ± SD
SCr serum creatinine, CNY Chinese yuan, CA community-acquired, HA hospital-acquired
aDefined as number of days with SCr tests divided by length of stay
bAdjusted for age, sex, comorbidities and frequency of SCr test
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Elderly patients were more likely to be exposed to
nephrotoxic drugs. Our data demonstrated that 38.6 %
of AKI cases in 65–80 years old group and 51.4 % in the
very elderly group were possibly drug induced, which is
much higher than 32.4 % of AKI cases in patients aged
18–64 years (Table 4). Renin angiotensin system inhibi-
tors and diuretics were not included in nephrotoxic drug
list in this study because they mainly impact on renal
perfusion. Of note, the use of Chinese traditional medi-
cine/remedies and NSAIDs were very common in elderly
patients, especially in patients older than 80 years. More
than one-third of very elderly patients had a history of
exposure to Chinese traditional medicine/remedies be-
fore AKI onset (Table 4).
Table 2 Risk factors for community- and hospital-acquired AKI in elderly patients
HA-AKI CA-AKI
Risk factors Frequency (%) OR (95%CI)a PAF Frequency (%) OR (95%CI)a PAF
Age
65-69 years Reference Reference
70-74 years 0.99 (0.9 to 1.09) 1.17 (1.01 to 1.37)
75-79 years 1.13 (1.02 to 1.24) 1.25 (1.07 to 1.47)
>80 year 1.1 (0.99 to 1.21) 1.68 (1.44 to 1.95)
Sex
Male 1.19 (1.1 to 1.29) 1.06 (0.94 to 1.2)
Comorbidity
CKD 15.5 4.62 (4 to 5.33) 24.8 16.4 4.85 (3.93 to 6) 26.5
Heart failure 15.3 1.56 (1.42 to 1.72) 8.8 15.7 1.2 (1.03 to 1.4) 2.8
CAD 26.1 1.28 (1.18 to 1.39) 6.4 26.5 0.86 (0.76 to 0.98)
Shock 1.3 2.05 (1.77 to 2.37) 3.7 1.6 4.57 (3.64 to 5.74) 6
Acute myocardial infarction 3.1 1.72 (1.48 to 2.01) 2.7 3.2 1.46 (1.11 to 1.92) 1.4
Stroke 13.5 1.17 (1.06 to 1.28) 2.6 13.3 1 (0.86 to 1.17)
Pneumonia 14 1.08 (0.99 to 1.18) 1.8 14.4 1.8 (1.58 to 2.05) 11.1
Gastrointestinal bleeding 2.2 1.33 (1.12 to 1.57) 1 2.3 1.59 (1.22 to 2.07) 1.5
Liver disease 2.3 1.37 (1.11 to 1.68) 0.7 2.3 1.2 (0.86 to 1.67) 0.4
Sepsis 0.6 1.25 (1 to 1.57) 0.5 0.8 2.55 (1.8 to 3.6) 1.6
Trauma 1 1.45 (1.12 to 1.87) 0.5 1 0.85 (0.51 to 1.41) -
Diabetes 18.6 1.02 (0.93 to 1.11) 0.3 18.9 1.11 (0.96 to 1.27) 1.8
Hematologic malignancy 2.2 1.14 (0.91 to 1.42) 0.3 2.3 1.44 (1.06 to 1.97) 0.8
Urinary tract obstruction 1.3 1.14 (0.86 to 1.51) 0.2 1.5 4.39 (3.41 to 5.66) 3.9
Burn 0 0.61 (0.09 to 4.34) 0 6.3 (1.37 to 28.99) 0.1
Rheumatic disease 1.5 1.01 (0.78 to 1.31) 1.5 1.15 (0.78 to 1.69) 0.2
Renal disease 2.1 0.93 (0.74 to 1.16) 2.3 1.88 (1.46 to 2.42) 2.2
tuberculosis 0.5 0.56 (0.29 to 1.09) 0.5 0.73 (0.29 to 1.8)
COPD 6 0.95 (0.82 to 1.09) 6.1 1.09 (0.89 to 1.33)
Solid cancer 25.8 0.92 (0.85 to 1) 24.8 0.61 (0.52 to 0.71)
Hypertension 39.1 0.93 (0.86 to 1.01) 39.3 0.94 (0.85 to 1.04)
Clinical setting for HA-AKI
Intensive care 11.3 2.42 (2.22 to 2.63) 19.4
Non-cardiac operation 45.1 1.17 (1.08 to 1.28) 6.8
Cardiac operation 1.3 2.19 (1.84 to 2.6) 3.8
Intervention operation 16.6 1.29 (1.17 to 1.43) 3.8
HA-AKI hospital-acquired AKI, CA-AKI community-acquired AKI, OR odds ratio, 95 % CI 95 % confidence interval, PAF population attributable fraction, CAD coronary
artery disease; Intensive care: Stay in ICU (intensive care unit) during hospitalization
aAdjusted for age, sex, comorbidities and clinical procedures
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In-hospital outcomes mortality
The mortality rate of AKI was 6.2 % in the young patient
group, 10.3 % in patients aged 65 to 80 and 19.6 % in pa-
tients older than 80 years (Table 5). There was a signifi-
cant association between mortality from AKI and the
severity of AKI in elderly patients. The HRs of in-
hospital death adjusted for age, sex, comorbidities, and
surgical procedures were 7.1, 15.2 and 29.7, respectively,
for stage 1, stage 2 and stage 3 of AKI (Table 6).
LOS and daily cost
The LOS and daily cost were similar in different patient
groups categorized by age (Table 5). However, significant
associations of AKI severity and LOS and daily cost dur-
ing hospitalization were observed in the elderly patient
group. In patients with AKI stage 3, the LOS was 19 days,
and the daily cost was 3450 yuan, which was much higher
than in patients with lower stages (Table 6).
Renal outcome
Of note, different patient groups categorized by age had
a similar proportion of patients requiring dialysis,
whereas the renal recovery rate was much lower in the
elderly patient group, especially in patients older than
80 years (33.8 %) (Table 5).
Table 3 Risk factors for AKI patients by age category
Risk factors 18–64 years 65–79 years ≥80 year
% OR (95 % CI)a PAF % OR (95 % CI)a PAF % OR (95 % CI)a PAF
Sex
Male 53.2 1.3 (1.22 to 1.38) 1.33 (1.21 to 1.45) 1.44 (1.25 to 1.66)
Comorbidity
CKD 4.1 4.31 (3.77 to 4.92) 10.4 13.2 5.64 (4.76 to 6.68) 21.6 26.7 6.89 (5.39 to 8.8) 30.7
Heart failure 5.4 3 (2.75 to 3.28) 6.9 13.8 1.86 (1.66 to 2.09) 7.5 21.2 1.4 (1.2 to 1.65) 5.7
Pneumonia 7.2 1.73 (1.6 to 1.86) 4.6 11.8 1.84 (1.66 to 2.04) 7.2 24.3 1.83 (1.6 to 2.09) 11.9
Shock 0.9 6.05 (5.19 to 7.05) 3.1 1.3 7.61 (6.07 to 9.56) 4.2 2.6 7.24 (5.3 to 9.89) 5.7
Stroke 5.2 1.4 (1.27 to 1.54) 1.7 11.7 1.28 (1.14 to 1.43) 2.4 19.9 1.2 (1.03 to 1.4) 2.7
Urinary tract obstruction 2.4 1.67 (1.47 to 1.9) 1.4 1.7 2.16 (1.71 to 2.72) 1.3 1.1 2.75 (1.72 to 4.39) 1
Liver disease 3.7 1.3 (1.16 to 1.46) 0.9 2.6 1.18 (0.94 to 1.47) 0.3 1.5 1.85 (1.21 to 2.84) 0.8
Sepsis 0.7 2.55 (2.08 to 3.12) 0.9 0.7 2.8 (2.01 to 3.9) 0.9 0.9 6.55 (3.9 to 11.02) 1.7
Gastrointestinal bleeding 1.5 1.49 (1.28 to 1.75) 0.7 2.1 1.49 (1.2 to 1.85) 0.9 3.2 1.72 (1.28 to 2.31) 1.5
Trauma 2.6 1.34 (1.17 to 1.53) 0.7 1 1.56 (1.15 to 2.12) 0.5 1 1.56 (0.89 to 2.73) 0.3
Acute myocardial infarction 1.3 1.82 (1.46 to 2.25) 0.6 3.1 2.04 (1.68 to 2.48) 2.1 3.5 2.18 (1.63 to 2.91) 2.4
Diabetes 8 1.08 (1 to 1.17) 0.6 17.9 0.94 (0.85 to 1.05) 21.6 0.9 (0.77 to 1.05)
Hypertension 13.3 1.02 (0.9 to 1.15) 0.3 36.2 0.88 (0.82 to 0.95) 48.9 0.94 (0.82 to 1.08)
Rheumatic disease 2.5 1.14 (1 to 1.31) 0.3 1.6 1.09 (0.83 to 1.45) 0.1 1.2 1.25 (0.74 to 2.1) 0.2
Hematologic malignancy 3.3 1.09 (0.95 to 1.24) 0.2 2.6 1.07 (0.85 to 1.35) 0.1 1.1 2.04 (1.26 to 3.29) 0.7
Burn 0.1 1.71 (1.04 to 2.82) 0.1 1.6 (0.33 to 7.73) 0 4.76 (0.42 to 54.08)
Renal disease 2.8 1.03 (0.9 to 1.16) 0.1 2.2 1 (0.8 to 1.25) 2.6 1.48 (1.05 to 2.09) 0.9
COPD 0.6 0.61 (0.44 to 0.84) 4.6 0.92 (0.77 to 1.09) 11 1.08 (0.89 to 1.31) 0.7
Tuberculosis 0.7 0.36 (0.24 to 0.55) 0.5 0.67 (0.37 to 1.25) 0.4 0.41 (0.1 to 1.76)
CAD 7.7 0.81 (0.74 to 0.89) 24 0.98 (0.89 to 1.07) 32.9 1.06 (0.91 to 1.23) 1.3
Solid cancer 28.8 0.8 (0.75 to 0.85) 27.5 1.06 (0.96 to 1.16) 1.1 17.9 1.15 (0.98 to 1.36) 1.7
HA-AKI hospital-acquired AKI, CA-AKI community-acquired AKI, OR odds ratio, 95 % CI 95 % confidence interval, PAF population attributable fraction, CAD coronary
artery disease
aAdjusted for age, sex, comorbidities and clinical procedures








Nephrotoxic drugs 32.4 38.6 51.4 <0.001
Chinese traditional
medicine/herbs
27.8 30.5 33.8 <0.001
NSAIDs 18.5 26.8 29.2 <0.001
Antibiotics 17.5 13.8 15.1 <0.001
Contrast media 6.1 8.3 7.7 <0.001
Anticancer drugs 4.8 2.7 0.7 <0.001
NSAIDs nonsteroidal anti-inflammatory drugs
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Discussion
In this large, retrospective cohort study conducted in
nine regional central hospitals across Northern, Central
and Southern China, we have determined the incidence
of AKI in Chinese elderly patients. By analyzing data
from both young and elderly groups, we also illustrate
risk factors and in-hospital outcomes of AKI in patients
aged more than 65 years.
In our previous study, we determined that the fre-
quency of SCr tests has a substantial impact on the de-
tection rate of AKI [5]. By using a novel approach after
adjusting for the frequency of SCr tests and other co-
founders, we have estimated the incidence of AKI in the
whole population at 11.6 %. The same method was used
in the analysis of elderly patients. The adjusted incidence
of AKI is 15.44 % in patients 65–80 years old and
22.22 % in patients older than 80 years, which is much
higher than in younger groups. It was reported that the
incidence rate of AKI is 14.8 % in Chinese very elderly
patients (≥80 years) [12] and 8.6 % in patients older than
65 years who received contrast-enhanced CT [14], which
is much lower than in our cohort because a large num-
ber of AKI patients were not detected by SCr
measurements. Among the 167.5 million patients (data
from National Health and Family Planning Commissions
of the Peoples’ Republic of China) [17], we estimate ap-
proximately 8.4 million elderly patients suffered from
AKI in 2013 in China, which is a huge medical burden.
In order to identify the contribution of different risk fac-
tors to AKI in elderly patients, PAF values were used in
this study. In both HA-AKI and CA-AKI groups, preexist-
ing CKD is a major risk factor for AKI. This may be ex-
plained by the susceptibility to kidney injury and greater
incidence of comorbidity in patients with CKD. Indeed,
another cohort including hospitalized patients at different
CKD stage demonstrated that the risk of AKI increased
with decreasing eGFR (8.9 % with eGFR ≥60 mL/min/1.73
m2vs 68.9 % with eGFR <30 mL/min/1.73 m2) [18]. In our
previous study, we found urinary tract obstruction was an
important risk factor for AKI [5]. The OR of urinary tract
obstruction in this study was 1.67 in patients aged 18–64
years, 2.16 in patients aged 65–79 years and 2.75 in pa-
tients older than 80 years, suggesting that elderly patients
with urinary tract obstruction were at higher risk for AKI.
However, the PAF of urinary tract obstruction decreased
when the patient population was getting older. This may
Table 5 Outcome of patients by age category
Outcome 18–64 years (%) 65–79 years (%) ≥80 year (%) P value
Non-AKI AKI Non-AKI AKI Non-AKI AKI
(n = 92391) (n = 9104) (n = 28934) (n = 4030) (n = 8061) (n = 1712)
Death (%)
All 371 (0.4) 561 (6.2) 251 (0.9) 416 (10.3) 173 (2.1) 336 (19.6) <0.001
AKI with dialysis — 14.8 — 35.7 — 52.6 <0.001
Dialysis (%) — 371 (5.6) — 129 (4.5) — 57 (5) 0.086
Recovery of HA-AKI (%) — 2684 (41.7 %) — 1098 (39.1 %) — 373 (33.8 %) <0.001
Length of stay (d) 13 (8,20) 17 (11,27) 13 (8,19) 17 (11,26) 14 (9,20) 17 (11,29) <0.001
Daily cost (CNY) 1752 (1052,3018) 2621 (1426,4636) 1673 (1047,3096) 2541 (1398,4462) 1510 (2542,1012) 2190 (1338,3863) <0.001
Length of stay and daily cost are presented in median (25th, 75th percentile)
The other cells are expressed as N (% within age and AKI strata)
HA-AKI hospital-acquired AKI, CNY Chinese yuan
Table 6 Outcome of elderly patients by AKI stages
Outcome S0 (n = 36995) S1 (n = 3457) S2 (n = 1187) S3 (n = 1098) P value
Structure of AKI <0.001
CA-AKI — 24.7 44.1 41.4
HA-AKI — 75.3 55.9 58.6
Death (%) 1.1 7.1 15.2 29.7 <0.001
Dialysis (%) — — — 25.9 —
Recovery of HA-AKI (%) — 42.3 33.6 22.6 <0.001
Length of stay(d) 13 (9,19) 16 (10,24) 18 (11,28) 19 (11,33) <0.001
Daily cost (CNY) 1630 (1038,2944) 2173 (1282,3872) 2534 (1481,4168) 3450 (1798,6035) <0.001
Length of stay and daily cost are presented in median (25th, 75th percentile)
The other cells are expressed as N (% within age and AKI strata)
HA-AKI hospital-acquired AKI, CNY Chinese yuan
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be explained by the lower frequency of urinary tract ob-
struction in elderly patients. This highlights the use of
ultrasound examination of urinary system in diagnosis of
AKI in elderly patients. Of note, polypharmacy was very
common in elderly patients [7]. Our study has shown that
elderly patients have a high proportion of exposure to
nephrotoxic drug, especially patients who use traditional
Chinese medicines, which is consistent with previous study
[12, 19, 20]. Although we could not identify the direct link
between use of traditional Chinese medicines and AKI,
more attention should be paid by physicians when pre-
scribing traditional Chinese medicines to elderly patients.
In line with our previous study, we have demonstrated
that in-hospital mortality, length of stay and daily cost in
the elderly group are higher than in the younger group
[21]. The mortality rate of AKI in our study (10.3 % in pa-
tients with age from 65 to 80 and 19.6 % in patients older
than 80 years) is consistent with previous study [21]. In
addition, the severity of AKI in elderly patients was associ-
ated with short-term outcomes and resource utilization.
Compared with patients with other stages of AKI, elderly
patients with Stage 3 AKI have lower recovery rates and
higher mortality and daily cost, which indicate that those
patients need special medical care in the clinical practice.
Even though this study included a large number of
patients from multiple centers in China and a novel analytic
approach was used, there are several limitations. First, esti-
mated incidence rate is an approximation of the true AKI
incidence because multiple or daily SCr tests are needed in
order to increase detection rate of AKI according to
KDIGO criteria. Second, urine output, another important
factor of AKI detection, is not used in this study because of
the lack of urinary data, which is also common in other
studies on patients from ICU and non-ICU departments
[20] However, this may lead to underdiagnosis of AKI [22].
Third, this study is retrospective research, and only in-
hospital outcomes were analyzed. Long-term follow data
are lacking. Fourthly, because this study lacks information
on albuminuria and proper diagnosis of CKD 1 and 2, we
could not analyze the data in patients with early stage
CKD and albuminuria. And we exclude patients with a
history of stages 4–5 CKD, maintenance dialysis or renal
transplantation, which is similar to other studies [6, 23].
Therefore, only patients with eGFR from 30 to 60 ml/min
are analyzed as patients with CKD in our study. Finally,
information about drug induced AKI in this study is lim-
ited because prescription data are not complete in non-
AKI patients and a uniform standard for identifying and
grading the effect of nephrotoxic drugs is not available.
Conclusion
In this large retrospective cohort study in China, we
have determined the incidence of AKI is 15.44 % in pa-
tients 65–80 years old and 22.22 % in patients older than
80 years by adjusting SCr test frequency. Compared with
young patients, older patients are more likely to develop
AKI, and their outcomes are worse. Early detection and
effective treatment of AKI in elderly patients should be
the focus of future research.
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